 |
Clobazam Please read this before proceeding: We have found a way to save you big money when ordering your medications. Simply join our site for only $9.95 per month & we will show you where you can fill your prescriptions at the lowest possible prices. Here is what you get when joining our site:
- A guarantee that you are purchasing at the lowest prices
- Peace of mind knowing you are buying FDA approved medications from legitimate pharmacies
- Secure online ordering from PharmacyChecker.com approved pharmacies
- 24/7 money back guarantee if you are at all dissatisfied
Special Notice: For a limited time, we are offering you unlimited access to our low prices for only $9.95 per month!
We guarantee that you will be purchasing at the lowest possible prices! Please select the quantity & dosage you desire and click "More Info" to continue.
Basic Information:Clobazam is a 1,5-benzodiazepine with antianxiety and anticonvulsant properties, advocated for the treatment of primary anxiety and that associated with organic or functional disorders.
Detailed Information:
Clobazam
Has a half-life of 18 hours, but that of the principal metabolite, N-desmethylclobazam, is about 50 hours. Although the metabolite is pharmacologically less active than the parent drug, steady-state plasma concentrations of the metabolite are 8 times higher than those of the unchanged drug. Therapeutic trials indicate that the antianxiety effect of clobazam 30 to 80 mg daily is comparable with that of half its dose of diazepam. Clobazam has minimal muscle relaxant and hypnotic activity. Although subjective drowsiness has occurred with similar frequency with clobazam and diazepam in some studies, clobazam causes less objectively measured sedation or psychomotor impairment in experimental studies. Results of studies of vigilance and psychomotor performance during therapeutic use in patients are less conclusive, but clobazam may be useful in anxious patients who experience such impairment with other benzodiazepines.
USAMedsOnline.com - Anti-Anxiety |
|
 |
| |
|
